Phio Pharmaceuticals Corp. (PHIO)

0.7760 +0.0110 (+1.44%) 市場開市。 截至 04:00PM EDT。

Phio Pharmaceuticals Corp.

11 Apex Drive
Suite 300A PMB 2006
Marlborough, MA 01752
United States
508-767-3861
https://www.phiopharma.com

版塊: Healthcare
行業: Biotechnology
全職員工: 8

高階主管

名稱	頭銜	支付	行使價	出生年份
Mr. Robert J. Bitterman	President, CEO & Chairman	380.25k	無	1951
Ms. Caitlin Kontulis	VP of Finance & Administration and Secretary	無	無	1986
Ms. Linda M. Mahoney	Senior Vice President of Development	無	無	無

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States. The company is developing PH-762, an INTASYL compound in Phase 1b dose-escalating clinical trials to reduce the expression of cell death protein 1 (PD-1), a protein that inhibits T cells' ability to kill cancer cells; and PH-762 treated double positive tumor infiltrating lymphocytes, which is in Phase 1 clinical trials to treat advanced melanoma and other advanced solid tumors. It is also developing PH-894, an INTASYL compound in IND enabling studies to silence BRD4, a protein that controls gene expression in both T cells and tumor cells, effecting the immune system and the tumor. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is headquartered in Marlborough, Massachusetts.

公司管治

截至 無 止，Phio Pharmaceuticals Corp. 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。